Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
Financial Post ·
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualized relapse rate (ARR) vs active comparator Ocrevus OPERETTA 2 Phase III […]
SOUTH SAN FRANCISCO, Calif. -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease control versus active comparators. These findings, alongside new Ocrevus ® (ocrelizumab) and Enspryng ® (satralizumab) data, will be featured across more than 40 abstracts at MSToronto2026 (10th ACTRIMS-ECTRIMS Meeting), held October 21 to 23 in Toronto. Highlights include a fenebrutinib late-breaking presentation and an Enspryng presentation in the “Best of MSToronto2026.” Read More